# Vancomycin resistance predicts increased mortality in patients with Enterococcus faecium bloodstream infections: a six-year experience at a large tertiary care Italian hospital

**Authors:** Lucia Graziani, Tommaso Giani, Alberto Farese, Nicoletta Di Lauria, Elisabetta Mantengoli, Eleonora Riccobono, Gian Maria Rossolini, Alessandro Bartoloni, Michele Spinicci, Marco Allinovi, Marco Allinovi, Giulia Bandini, Lapo Bencini, Stefano Bongiolatti, Manuela Bonizzoli, Luca Bucciardini, Fabio Cianchi, Carlo Di Mario, Ilaria Galeotti, Andrea Galli, Elena Giacomelli, Elisa Giommoni, Stefano Gitto, Gian Luca Grazi, Maddalena Grazzini, Alessandra Ipponi, Regina Maria Lammel, Ilaria Liguori, Lorenzo Livi, Andrea Minervini, Elisabetta Neri, Fabrizio Niccolini, Matteo Piccini, Filippo Pieralli, Paolo Prosperi, Stefano Romagnoli, Mattia Ronchetti, Carlo Rostagno, Bernardo Salani, Massimo Sangiovanni, Sergio Serni, Alessandra Sorano, Pierluigi Stefano, Andrea Ungar, Renato Valenti, Simone Vanni, Silvia Vigiani

PMC · DOI: 10.1093/jac/dkag069 · Journal of Antimicrobial Chemotherapy · 2026-03-06

## TL;DR

Vancomycin-resistant Enterococcus faecium bloodstream infections are linked to higher mortality rates compared to vancomycin-susceptible infections.

## Contribution

Vancomycin resistance is identified as an independent predictor of mortality in E. faecium bloodstream infections.

## Key findings

- Vancomycin-resistant E. faecium infections had a 46% mortality rate compared to 29% in vancomycin-susceptible cases.
- Vancomycin resistance was confirmed as an independent mortality predictor in multivariate analysis.
- Delayed targeted therapy initiation was observed in vancomycin-resistant cases.

## Abstract

To report on clinical outcomes associated with vancomycin-resistant Enterococcus faecium (VRE) Bloodstream infections (BSIs) observed during a 6-year period at a hospital from an area of high VRE endemicity.

Retrospective study of patients with VRE and/or vancomycin-susceptible E. faecium (VSE) BSI in an Italian tertiary care hospital from January 2018 to December 2023.

The cohort included 116 VRE and 225 VSE BSIs. The baseline characteristics were comparable in both populations. Almost half VRE population (53/116, 46%) received no or ineffective empiric therapy against VRE. A targeted effective therapy was initiated with a mean delay of 2.2,  ± 0.4 days in the VRE patients and of 1.2 ± 0.1 days (P < 0.01) in the VSE patients. The univariate analysis showed higher rates of septic shock in the VRE group (60% versus 40%, P < 0.01), and the 30-day mortality rate was 29% and 46% in VSE and VRE BSIs, respectively (P < 0.01). By multivariate analysis, Sequential Organ Failure Assessment score (HR 1.25; 95% CI 1.19–1.31, P < 0.001), Charlson Comorbidity Index (HR 1.14; 95% CI 1.06–1.22, P = 0.001) and vancomycin resistance (HR 1.93; 95% CI 1.33–2.82, P = 0.001) resulted as independent predictors of mortality. The statistical association was confirmed in a sensitive analysis after removing polymicrobial BSI.

E. faecium BSIs confirmed to be associated with high mortality rate, especially in fragile patients. Moreover, vancomycin resistance is an independent mortality factor. Further studies are needed to identify patients at higher risk for E. faecium BSI.

## Linked entities

- **Chemicals:** vancomycin (PubChem CID 14969)
- **Species:** Enterococcus faecium (taxon 1352)

## Full-text entities

- **Diseases:** septic shock (MESH:D012772), BSIs (MESH:D018805), Organ Failure (MESH:D009102)
- **Chemicals:** Vancomycin (MESH:D014640)
- **Species:** Homo sapiens (human, species) [taxon 9606], Enterococcus faecium (species) [taxon 1352]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13016866/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13016866/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC13016866/full.md

---
Source: https://tomesphere.com/paper/PMC13016866